Feline Infectious Peritonitis (FIP) is an immune-mediated, systemic disease in cats that develops after mutation of Feline Coronavirus (FCoV) and has historically been regarded as fatal. FCoV is very common in cats, with 80-90% seroprevalence in multi-cat households, yet only 5-10% of exposed cats develop FIP. In recent years, antiviral agents such as GS-441524 and molnupiravir have changed the treatment landscape. This article reviews the pathophysiology of FIP, its clinical forms (wet and dry), diagnostic approach, current treatment options, and nutritional supportive-care strategies.
Situations Requiring Urgent Veterinary Attention
- Abdominal distension (ascites), especially when it develops rapidly in kittens or young cats
- Difficulty breathing caused by pleural effusion
- Persistent high fever (>39.5°C) that does not respond to antibiotics
- Jaundice involving the mucosa, inner ear surface, or sclera
- Neurologic signs such as gait abnormalities, seizures, or behavioural change
- Ocular involvement such as uveitis, iris colour change, or intraocular cloudiness
- Rapid weight loss together with anorexia and lethargy
1. The Relationship Between FCoV and FIP: Pathophysiology
From FCoV to FIP
Feline Enteric Coronavirus (FECV) infects the intestinal epithelium. In most cats, infection is asymptomatic or causes only mild diarrhoea. Transmission occurs by the fecal-oral route. It is common in multi-cat households.
An internal mutation occurs in FCoV, particularly within the spike protein and the 3c gene. The virus gains macrophage tropism and spreads beyond the intestine. This mutation occurs within the affected individual cat.
The mutated virus (FIPV) replicates in macrophages and triggers immune-mediated vasculitis. Type III and IV hypersensitivity reactions drive organ damage. If cell-mediated immunity is inadequate, FIP develops.
Why Does Not Every FCoV Infection Become FIP?
FIP develops through the interaction between viral mutation and the cat's immune response. Cats with strong cell-mediated immunity (CMI) may control the mutant virus. Cats with weaker CMI responses, especially under stress, at a young age, with genetic susceptibility, or with FIV/FeLV coinfection, are at higher risk. FIP itself is not contagious; what spreads is FCoV, not FIP (Pedersen, 2014).
2. Risk Factors
| Risk Factor | Explanation |
|---|---|
| Age | Most common between 3 months and 2 years; a second peak may occur after 10 years of age |
| Multi-cat household / shelter | High FCoV prevalence increases the likelihood of mutation |
| Breed | Reported more often in some pure breeds such as Birman, Ragdoll, Bengal, Abyssinian, and Rex |
| Stress | Moving, neutering, shelter housing, and similar stressors may suppress immunity |
| FIV / FeLV | Immunosuppression and impaired cell-mediated immunity |
| Genetic predisposition | Certain MHC haplotypes and familial susceptibility have been described |
3. Clinical Forms
Frequency: 60-70%
- Ascites: Abdominal enlargement caused by yellow, viscous, high-protein fluid
- Pleural effusion: Dyspnoea and tachypnoea
- Fever: High and unresponsive to antibiotics
- Anorexia and weight loss
- Jaundice: Present in a proportion of cases
- Rapid progression: Days to weeks
- Effusion analysis is highly helpful diagnostically
Frequency: 30-40%
- Organ granulomas: Kidney, liver, lungs, mesenteric lymph nodes
- Ocular disease: Uveitis, iris colour change, keratic precipitates (about 30%)
- Neurologic disease: Ataxia, tremor, seizures, paresis, behavioural change (about 10%)
- Fever: Chronic and fluctuating
- Weight loss and anorexia
- Slower progression: Weeks to months
- Diagnosis is more difficult because there is no effusion
Mixed Form
Some cats show wet and dry disease simultaneously or in sequence. A cat may initially present with the wet form and later shift toward a dry pattern during treatment, or vice versa. Neurologic and ocular involvement can accompany either form.
4. Diagnostic Approach
FIP remains one of the most difficult diagnoses in feline medicine. No single antemortem test is definitively diagnostic; diagnosis relies on the combination of clinical signs, laboratory findings, and imaging:
| Test | Finding | Diagnostic Value |
|---|---|---|
| Effusion analysis | Yellow, viscous fluid; protein >3.5 g/dL; A:G ratio <0.4; positive Rivalta test | High — the most useful test in wet FIP |
| Rivalta test | Effusion mixed with acetic acid forms a white gelatinous drop when positive | High sensitivity (91%), moderate specificity (66%) |
| Serum biochemistry | Hyperglobulinaemia (A:G ratio <0.6), hyperbilirubinaemia | Supportive, but not diagnostic on its own |
| Serum protein electrophoresis | Polyclonal gammopathy with increased α2 and γ fractions | Supportive |
| FCoV antibody titre | High titre | Low — indicates exposure, not a diagnosis of FIP |
| RT-PCR (effusion/tissue) | Detection of FCoV RNA | Moderate to high in effusion; low in blood |
| Immunohistochemistry (IHC) | Demonstration of FCoV antigen within macrophages in tissue biopsy | Gold standard, but invasive |
| Ultrasound / radiography | Effusion, organ granulomas, lymphadenopathy | Supportive imaging findings |
A Common Diagnostic Mistake
A positive FCoV antibody test does NOT equal FIP. It only shows that the cat has been exposed to coronavirus, and 80-90% of cats in multi-cat households may be positive. Antibody testing alone is never sufficient to diagnose FIP. A negative result does not exclude FIP either, because about 10% of cats with FIP are seronegative.
5. Treatment: The GS-441524 Revolution
FIP was historically considered fatal. Since 2018-2019, the discovery of antiviral treatment has changed that paradigm:
| Drug | Mechanism | Use | Note |
|---|---|---|---|
| GS-441524 | Nucleoside analogue; inhibits viral RNA polymerase | Subcutaneous injection or oral treatment; 84 days (12 weeks) | Most widely used; 80%+ remission in Pedersen studies; still unlicensed in many countries |
| Molnupiravir | Nucleoside analogue; induces viral RNA mutagenesis | Oral administration; easier to use | Human COVID-19 drug; off-label in cats; alternative to GS-441524 |
| GC376 | Protease inhibitor | Subcutaneous injection | Less commonly used; combination with GS-441524 is being investigated |
| Remdesivir | Prodrug of GS-441524 | Intravenous use as an initial treatment option | The active metabolite is GS-441524; may be used in hospital settings at the start of therapy |
5.1 GS-441524 Treatment Protocol
General Treatment Framework
Wet Form
- Dose: 4-6 mg/kg/day SC
- Duration: 84 days (12 weeks)
- Effusion usually starts to decrease within 1-2 weeks
- Clinical improvement is often obvious within 3-5 days
Dry Form
- Dose: 6-8 mg/kg/day SC
- Duration: 84 days (12 weeks)
- Granulomas resolve more slowly
- Higher doses may be required
Neurologic / Ocular Form
- Dose: 8-10 mg/kg/day SC
- Duration: 84 days or longer
- Drug penetration across the blood-brain barrier is critical
- Response to treatment is usually slower
Monitoring: Check body weight, temperature, and appetite weekly. Repeat blood work every 4 weeks, including globulins, A:G ratio, bilirubin, and ALT. Observe for 3 months after treatment completion; relapse is reported in 5-15% of cases.
Access to GS-441524 and Treatment Cost
In many countries, GS-441524 is not yet officially licensed for veterinary use. Some countries such as Australia and the United Kingdom have created legal access pathways. In Turkey there is currently no official licence, and owners may obtain the drug through different channels. The cost of a 12-week course varies according to body weight and the source of the product. Veterinary supervision is essential for dose adjustment, monitoring, and relapse assessment.
5.2 Supportive Therapy
| Support | Explanation |
|---|---|
| Fluid therapy | IV or SC support to correct dehydration and stabilise electrolytes |
| Antiemetic | Maropitant (Cerenia) for nausea and vomiting control |
| Appetite stimulant | Mirtazapine, often critical in anorectic cats |
| Abdominal drainage | Temporary symptomatic relief in severe ascites |
| Thoracocentesis | Urgent when pleural effusion causes respiratory distress |
| Anti-inflammatory treatment | Prednisolone may be used as palliation until antiviral therapy starts or if antivirals are unavailable |
6. Nutritional Support: The VetKriter Approach
VetKriter Nutrition Principle
Nutritional support is vital in cats with FIP. These patients are often severely anorectic, cachectic, and dehydrated. Adequate calorie and protein intake directly affects response to treatment. During therapy, the most important goals are to keep the cat eating, gaining weight, and staying hydrated.
- High-calorie, high-protein food: To counter cachexia and muscle loss
- Wet food: Supports hydration and often has a stronger aroma that encourages intake
- Warm the food: To about 38°C to increase aroma
- Small, frequent meals: 4-6 times daily
- Different flavours and textures: Useful when food acceptance is poor
- Hand feeding: If necessary, a small amount can be offered on the fingertip or palate
- Omega-3 (EPA/DHA): Anti-inflammatory support that may help reduce vasculitis
- Antioxidants: Vitamin E, vitamin C, and selenium for oxidative stress support
- B vitamins: For energy metabolism and appetite support
- High-quality protein: To support immunoglobulin synthesis and preserve lean mass
- Probiotics: Particularly if antibiotics are used; may support the gut-associated lymphoid tissue
- Iron: In cases of anaemia, but only under veterinary supervision
Feeding Priority in an Anorectic Cat With FIP
In FIP treatment, the principle is that eating something is better than eating nothing. If the cat prefers an ordinary diet instead of a renal, dental, or other therapeutic diet, feed what the cat will accept. During treatment, the first priority is getting the cat to eat and regain weight; ideal food selection is secondary. If anorexia lasts longer than 48 hours, feeding-tube support such as an esophagostomy tube should be considered.
7. Control of FCoV Transmission
Managing FCoV in Multi-cat Homes
Reducing Transmission:
- Litter box hygiene: Clean 1-2 times daily; number of litter boxes = number of cats + 1
- Litter box placement: Keep boxes away from food and water bowls
- Disinfection: FCoV is an enveloped virus and is susceptible to most disinfectants
- Population control: Limit cat density and introduce new cats carefully
In a Home With a Cat Diagnosed With FIP:
- FIP itself does not spread from cat to cat; what spreads is FCoV
- Other cats in the home have most likely already been exposed to FCoV
- Before adding a new cat, consider FCoV antibody screening and wait about 3 months
- Do not panic: Exposure to FCoV does not mean the cat will develop FIP
8. Prognosis
| Situation | Prognosis |
|---|---|
| Untreated FIP | Fatal: wet form usually progresses over days to weeks; dry form over weeks to months |
| GS-441524 treatment (wet form) | 80-90% remission; prognosis is good when treatment is started early |
| GS-441524 treatment (dry form) | 65-80% remission; higher doses and longer treatment may be necessary |
| Neurologic FIP | 50-65% remission; the most challenging form, usually requiring higher doses and longer treatment |
| Relapse rate | About 5-15%, usually within the first 3 months after treatment ends |
9. References
- Pedersen NC. An update on feline infectious peritonitis: virology and immunopathogenesis. Vet J. 2014;201(2):123-132.
- Pedersen NC, et al. Efficacy and safety of the nucleoside analog GS-441524 for treatment of cats with naturally occurring feline infectious peritonitis. JFMS. 2019;21(4):271-281.
- Jones S, et al. Unlicensed GS-441524-like antiviral therapy can be effective for at-home treatment of feline infectious peritonitis. Animals. 2021;11(8):2257.
- Addie DD, et al. Feline Infectious Peritonitis — ABCD Guidelines on Prevention and Management. JFMS. 2009;11(7):594-604.
- Dickinson PJ, et al. Antiviral treatment using the adenosine nucleoside analogue GS-441524 in cats with clinically diagnosed neurological feline infectious peritonitis. JVIM. 2020;34(4):1587-1593.
- Tasker S. Diagnosis of Feline Infectious Peritonitis: Update on Evidence Supporting Available Tests. JFMS. 2018;20(3):228-243.
- WSAVA Global Nutrition Committee. Nutritional Assessment Guidelines. 2024.